ReviewJournal of investigative medicine high impact case reports
Occult Breast Carcinoma Presenting with Extensive Bone Involvement in the Absence of an Identifiable Primary Breast Lesion: A Case Report.
Review in Journal of investigative medicine high impact case reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Occult breast cancer (OBC) is a rare and diagnostically challenging subtype of breast carcinoma characterized by axillary or distant metastases without an identifiable primary breast lesion. We report an unusual presentation of OBC in a patient with diffuse osteolytic bone metastases and axillary lymphadenopathy in the absence of clinically palpable, mammographically, or sonographically detectable breast lesions. The diagnosis was established through bone marrow biopsy and immunohistochemical analysis. Review of the literature identified only four previously reported cases of OBC initially presenting with diffuse osseous metastases, three of which were hormone receptor-positive. This case highlights the importance of maintaining a high index of suspicion for OBC in patients with metastatic adenocarcinoma of unknown primary origin with diffuse skeletal involvement. Furthermore, it underscores the distinct biologic behavior of hormone receptor-positive breast cancer, which preferentially metastasizes to bone and may achieve durable disease control with endocrine-based therapy, allowing selected patients to avoid cytotoxic chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.